Leukemia Clinical Trials

Phase I Agents for Hematologic Malignancies

• Ruxolitinib (2012-0697) (NCT01751425)
• AC220 + LD Ara-C (2012-1047) (NCT01892371)
• GSK525762 (2013-0527) (NCT01943851)
• MEDI4736 (2013-1041) (NCT02117219)
• FF-10501-01 (2014-0014) (NCT02193958)
• Ruxolitinib + DAC (2014-0344) (NCT02257138)
• OPN-305 (2014-0432) (NCT02363491)/ (2017-0887) (NCT03337451)
• Bosutinib + Inotuzumab (2014-0435) (NCT02311998)
• DS-3032B (2014-0565) (NCT02319369)
• ONC201 (2014-0731) (NCT02392572)
• BGB324 (2014-0756) (NCT02488408)
• SL-401(2014-0860) (NCT02270463)
• SL-401(2014-0976) (NCT02268253)
• AMG 330 (2015-0296) (NCT02520427)
• LY2510924 + Ida + Ara-C (2015-0436) (NCT02652871)
• FT-1101 (2015-0516) (NCT02543879)
• ADCT-402 (2015-0618) (NCT02588092)
• LY2606368 + Ara-C + Flu (2015-0665) (NCT02649764)
• AG-120 or AG-221 + 7+3 (2015-0767) (NCT02632708)
• BLU-285 (2015-0832) (NCT02561988)
• Venetoclax + Cobimetinib or Venetoclax + Idasanutlin (2015-0898) (NCT02670044)
• ADCT-402 (2015-0985) (NCT02669264)
• IMGN779 (2015-1024) (NCT02674763)
• AG-120 or AG-221 + AZA (2015-1056) (NCT02677922)
• FT-2102 (2016-0150) (NCT02719574)
• XmAb 14045 (2016-0165) (NCT02730312)
• ORH-2014 (2016-0291) (NCT03048344)
• CD33-CAR-T (2016-0341) (NCT03126864)
• H3B-8800 (2016-0547) (NCT02841540)
• INCB059872 (2016-0556) (NCT02712905)
• AMV564 (2016-0646) (NCT03144245)
• AGS62P1 (2016-0647) (NCT02864290)
• K0706 (2016-0648) (NCT02629692)
• Palbociclib (2016-0772) (NCT03132454)
• UCART123 in BPDCN (2016-0840) (NCT03203369)
• Venetoclax + AZA (2016-0944) (NCT02966782)
• CWP232291 + Ara-C (2016-1071) (NCT03055286)
• BAY 1251152 (2016-1114) (NCT02745743)
• DS-3201b (2016-1130) (NCT03110354)
• MGD006 (2017-0027) (NCT02152956)
• Ulocuplumab + LD Ara-C (2017-0092) (NCT02305563)
• ABBV-744 (2017-0172) (NCT03360006)
• AMG 176 (2017-0776) (NCT02675452)
• IMGN632 (2017-0855) (NCT03386513)
• S64315 (2017-0900) (NCT02979366)
• SEL24 (2016-0713) (NCT03008187)
• PCM-075 + LDAC (2017-0480) (NCT3303339)
• LGH447 (2017-0592) (NCT02078609)

Acute Lymphoblastic Leukemia (ALL)

Newly Diagnosed or Previously Treated

• Hyper-CVAD + INO (2015-0922) (NCT03488225)
• mHCVD + Inotuzumab +/-Blinatumomab (2010-0991) (NCT01371630)
• Venetoclax + Chemo (2016-0694) (NCT03319901)
• Hyper-CVAD + Nelarabine (2006-0328) (NCT00501826)
• Hyper-CVAD + Ponatinib (2011-0030) (NCT01424982)
• Blinatumomab + Ponatinib (2016-0792) (NCT03263572)
• Bosutinib + Inotuzumab (2014-0435) (NCT02311998)
• Hyper CVD + Ponatinib (2016-0402) (NCT03147612)
• EPOCH + Ofatumumab or Rituximab (2014-0123) (NCT02199184)

Minimal Residual Disease

• Blinatumomab (2014-0844) (NCT02458014)
• Inotuzumab (2015-0921) (NCT03441061)

Salvage Programs

• Hyper-CVAD + CMC-544 (2010-0991) (NCT01371630)
• KTE-C19 (2015-0416) (NCT02614066)
• Chemo + Blinatumomab (2017-0127) (NCT03518112)
• ADCT-402 (2015-0985) (NCT02669264)
• UCART19 (2016-0725) (NCT02746952)
• iC9/CAR (2016-0641) (NCT03056339)
• Inotuzumab (2015-0870) (NCT03094611)
• Venetoclax + Navitoclax + Chemo (2017-0679) (NCT03181126)
• Ruxolitinib or Dasatinib + HyperCVAD (2014-0521) ( NCT02420717)
• ADCT-301 (2015-0618) (NCT02588092)
• EPOCH + Ofatumumab (2014-0123) (NCT02199184)
• CEC + VCR + Bortezomib (2016-0211) (NCT03136146)
• Blinatumomab + Ponatinib (2016-0792)  (NCT03263572)
• Bosutinib + Inotuzumab (2014-0435)  (NCT02311998)
• Hyper CVD + Ponatinib (2016-0402) (NCT03147612)
• BL-8040 + Nelarabine (2016-1101) (NCT02763384)
• Hyper-CVAD + Nelarabine (2006-0328) (NCT00501826)

Phase I/II Open to ALL

• mHCVD + Inotuzumab +/- Blinatumomab (2010-0991) (NCT01371630)
• KTE-C19 (2015-0416) (NCT02614066)
• ADCT-402 (2015-0985) (NCT02669264)
• DS-3201B (2016-1130) (NCT03110354)
• FT-1101 (2015-0516) (NCT02543879)
• ONC201 (2014-0731) (NCT02392572)

Acute Myelogenous Leukemia (AML)

Newly Diagnosed

• Fludarabine + Ara-C + G-CSF + Gemtuzumab (2007-0147) (NCT00801489)
• ATRA and arsenic +/- Gemtuzumab (2010-0981) (NCT01409161)
• Nivolumab + Ida + Ara-C (2014-0907) (NCT02464657)
• Cladribine + Ida + Ara-C (2012-0648) (NCT02115295)
• FLAG-Ida + Venetoclax (2016-0979) (NCT03214562)
• BP1001 + LD Ara-C (2016-0128) (NCT02781883)
• Venetoclax/Placebo + LDAC (2017-0398) (NCT03069352)
• Pracinostat + AZA (2017-0173) (NCT03151408)
• Cladribine + LD Ara-C alternating DAC (2011-0987) (NCT01515527)
• Nivolumab + AZA (2014-0861) (NCT02397720)
• Venetoclax + Decitabine (2017-0912) (NCT03404193)
• Venetoxlax + AZA vs AZA (2016-0985) (NCT02993523)
• DAC (2012-1017) (NCT01786343)
• Inecalcitol + DAC (2016-0198) (NCT02802267)
• Venetoclax/Placebo + LDAC (2017-0398) (NCT03069352)
• AML123 (2017-0559) (NCT03190278)
• PCM-075 + LDAC (2017-0173) (NCT03151408)
• AG-120 or AG-221 + AZA (2015-1056) (NCT02677922)
• PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
• SL401 + AZA (2017-0354) (NCT03113643)
• SGI-110 (2013-0843) (NCT02096055)
• Ulocuplumab + LD Ara-C (2017-0092) (NCT02305563)

FLT3 Mutated Only

• ASP2215 vs ASP2215 + AZA vs AZA (2016-0266) (NCT02752035)
• AC220 + AZA or LD Ara-C (2012-1047) (NCT01892371)

IDH Mutated only

• FT-2102 (2016-0150) (NCT02719574)
• AG120 (2017-0490) (NCT03471260)
• AG-120/placebo + AZA (2017-0848) (NCT03173248)
• AG-120 or AG-221 +7 + 3 (2015-0767) (NCT02632708)
• BAY 1436032 (2016-1084) (NCT03127735)
• IDH inhibitors + AZA (2015-1056) (NCT02677922)

Frontline AML Post-Hypomethylating Therapy for MDS

• Nivolumab + AZA (2014-0861) (NCT02397720)
• Venetoclax/Placebo + LDAC (2017-0398) (NCT03069352)

Secondary Leukemia

• Ruxolitinib + DAC (2014-0344) (NCT02257138)

Mixed Phenotype Acute Leukemia

• Clofarabine, Ida, Ara-C, VCR, and Corticosteroids (2013-0073) (NCT02135874)

Salvage

FLT3 Positive at relapse

• AlloSCT Initial Salvage Therapy (2014-0358) (NCT02441803)
• AC220 + LD Ara-C (2012-1047) (NCT01892371)
• Palbociclib (2016-0772) (NCT03132454)
• CD33-CAR-T (2016-0341) (NCT03126864)
• Venetoclax + Decitabine (2017-0912) (NCT03404193)
• Cladribine + Ida + Ara-C + Sorafenib (2012-0648) (NCT02115295)
• SY-1425 (2016-0460) (NCT02807558)
• AMG 330 (2015-0296) (NCT02520427)
• XmAb 14045 (2016-0165) (NCT02730312)
• FLAG-Ida + Venetoclax (2016-0979) (NCT03214562)
• Selinexor + Sorafenib (2014-0975) (NCT02530476)
• AMG673 (2017-0365) (NCT03224819)
• PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
• Daratumumab (2016-0889) (NCT03067571)

RAS Mutated

• AlloSCT Initial Salvage Therapy (2014-0358) (NCT02441803)
• FLAG-Ida + Venetoclax (2016-0979) (NCT03214562)
• Venetoclax + Decitabine (2017-0912) (NCT03404193)
• CD33-CAR-T (2016-0341) (NCT03126864)
• SY-1425 (2016-0460) (NCT02807558)
• AMG 330 (2015-0296) (NCT02520427)
• AMG673 (2017-0365) (NCT03224819)
• PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
• Daratumumab (2016-0889) (NCT03067571)

AML with MLL gene at 11q23 Translocations

• SY-1425 (2016-0460) (NCT02807558)

IDH Mutated

• AlloSCT Initial Salvage Therapy (2014-0358) (NCT02441803)
• FT-2102 (2016-0150) (NCT02719574)
• AG120 (2017-0490) (NCT03471260)
• Venetoclax + Decitabine (2017-0912) (NCT03404193)
• CD33-CAR-T (2016-0341) (NCT03126864)
• SY-1425 (2016-0460) (NCT02807558)
• AMG 330 (2015-0296) (NCT02520427)
• XmAb 14045 (2016-0165) (NCT02730312)
• PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
• Daratumumab (2016-0889) (NCT03067571)
• AG-120 (2017-0531) (NCT03245424)

All others (Regardless of mutation status)

• Alvocidib (Flavopiridol)/Ara-C/Mitoxantrone (FLAM) (2015-0719) (NCT02520011)
• AlloSCT Initial Salvage Therapy (2014-0358) (NCT02441803)
• CD33-CAR-T (2016-0341) (NCT03126864)
• FLAG-Ida + Venetoclax (2016-0979) (NCT03214562)
• Cladribine + Ida + Ara-C + Sorafenib (2012-0648) (NCT02115295)
• SY-1425 (2016-0460) (NCT02807558)
• Nivolumab + 5-AZA (2014-0861) (NCT02397720)
• LY2606368 + Ara-C + Flu (2015-0665) (NCT02649764)
• Venetoclax + Decitabine (2017-0912) (NCT03404193)
• DS-3032B (2014-0565) (NCT02319369)
• AMG 330 (2015-0296) (NCT02520427)
• XmAb 14045 (2016-0165) (NCT02730312)
• AML123 (2017-0559) (NCT03190278)
• ADCT-301 (2015-0618) (NCT02588092)
• Avelumab (2016-0444) (NCT02953561)
• SGN-CD123 (2016-0454)
• OX40 (2017-0337) (NCT03390296)
• GO + Glasdegib (2017-0337) (NCT03390296)
• AMG673 (2017-0365) (NCT03224819)
• Daratumumab (2016-0889) (NCT03067571)
• IACS-010759 (2016-0250) (NCT02882321)
• SL401 + AZA (2017-0354) (NCT03113643)
• MGD006 (2017-0027) (NCT02152956)
• PDR001/MBG453 + Decitabine (2017-0256) (NCT03066648)
• SGI-110 (2016-0828) (NCT02920008)

Maintenance (Patients in CR)

• SL-401 (2014-0860) (NCT02270463)
• Lenalidomide (2014-0116) (NCT02126553)
• Nivolumab (2015-0213) (NCT02532231)
• BL-8040 + Atezolizumab (2017-0926) (NCT03154827)
• Cyclophosphamide (2016-0227) (NCT02709993)

Supportive Care for AML

• Isavuconazole (2016-0373) (NCT03019939)
• NLA101 (2017-0259) (NCT03301597)

BPDCN Treatment Priorities

• SL-401 (2013-0979) (NCT02113982)
• UCART 123 (2016-0840) (NCT03203369)

Myelodysplastic Syndrome (MDS) (Includes CMML)

Specific Situations

Hypoplastic MDS and aplastic anemia

• Horse ATG (2012-0334) (NCT01624805)
• BL-8040 (2015-0408) (NCT02462252)

Splicing Mutations

• H3B-8800 (2016-0547) (NCT02841540)

MDS/MPN

• Ruxolitinib + AZA (2012-0737) (NCT01787487)
• SL-401 (CMML) (2014-0976) (NCT02268253)
• ORH-2014 (2016-0291) (NCT03048344)

FLT3 Positive

• AC220 + LD Ara-C (2012-1047) (NCT01892371)

RAS Mutated

• MEK162 (2013-0116) (NCT02089230)

IDH 1 Mutations

• FT-2102 (2016-0150) (NCT02719574)
• AG221 (2016-0981) (NCT03383575)

Low Risk/IPSS Int-1

• ASTX727-02 (2017-0886) (NCT03306264)
• OPN-305 (2014-0432)/(2017-0887) (NCT02363491)
• DAC vs AZA (2014-0112) (NCT02269280)
• Roxadustat (FG-4592)/Placebo (2017-0042) (NCT03263091)

IPSS int-2 or high

• Venetoclax + AZA vs AZA Alone (2016-0757) (NCT02942290)
• ASTX727-02 (2017-0886) (NCT03306264)
• Nivolumab + Ipilimumab + Aza (2014-0930) (NCT02530463)
• SGI-110 (2013-0901) (NCT02131597)
• Pembrolizumab + AZA (2016-0343) (NCT03094637)
• CB-839 + AZA (2016-0636) (NCT03047993)
• Oral Rigosertib + AZA (2013-0030) (NCT01926587)
• Cladribine + LD Ara-C alt DAC (2011-0987) (NCT01515527)
• Cladribine + Ida + Ara-C + Sorafenib (2012-0648) (NCT02115295)

Post Hypomethylating Agents

• OPN-305 (2014-0432)/ (2017-0887) (NCT02363491)
• Nivolumab + Ipilimumab + Aza (2014-0930) (NCT02530463)
• SGI-110 (2016-0587) (NCT02907359)
• Pembrolizumab + AZA (2016-0343) (NCT03094637)
• Venetoclax + AZA (2016-0944) (NCT02966782)
• Omacetaxine (2013-0870) (NCT02159872)
• AMV564-201 (2018-0009) (NCT03516591)
• Rigosertib (2015-0360) (NCT02562443)
• CB-839 + AZA (2016-0636) (NCT03047993)
• Oral Rigosertib + AZA (2013-0030) (NCT01926587)
• FF-10501-01 (2014-0014) (NCT02193958)
• Cladribine + Ida + Ara-C + Sorafenib (2012-0648) (NCT02115295)
• MEDI4736 (2013-1041) (NCT02117219)

Chronic Lymphocytic Leukemia (CLL)

CLL Immunotherapy

Untreated - early stage

• Ruxolitinib (2015-0570) (NCT03041636)
• Ibrutinib (2017-0039) (NCT03207555)

Untreated - all stages

• FCIG (2015-0281) (NCT02629809)
• Venetoclax + Ibrutinib (2015-0860) (NCT02756897)
• CC-122 (2015-0193) (NCT02406742)
• Atezolizumab (2015-1097) (NCT02846623)

Consolidation and Minimal Residual Disease (MRD)

• ABT-199 + Ibrutinib (2016-0785) (NCT03128879)

Prior Therapy

• UC-961 + Ibrutinib (2017-0889) (NCT03088878)
• CC-122 (2015-0193) (NCT02406742)
• JCAR017 (2017-0751) (NCT03331198)
• XmAb®13676 (2016-0991) (NCT02924402)
• SNS-062 – BTK-Inhibitor (2017-0158) (NCT03037645)
• Lenalidomide + Obinutuzumab (2014-0115) (NCT02225275)
• Nivolumab + Ibrutinib (2014-0931) (NCT02420912)
• Venetoclax + Ibrutinib (2015-0860) (NCT02756897)
• iC9/CAR (2016-0641) (NCT03056339)

Richter’s Transformation

• Nivolumab + Ibrutinib (2014-0931) (NCT02420912)
• Blinatumomab (2016-0765) (NCT03121534)
• EPOCH-R + VEN (2016-0900) (NCT03054896)

Other Studies

• PCI-32765 in Hairy Cell Leukemia (2013-0299) (NCT01841723)
• 2CDA + Rituximab in Hairy Cell Leukemia (2004-0223) (NCT00412594)

Chronic Myelogenous Leukemia (CML)

Chronic phase

• Dasatinib (2015-1040) (NCT02689440) HOLD
• K0706 (2016-0648) (NCT02629692)
• Ponatinib (2015-0212) (NCT02467270)
• Axitinib + Bosutinib (2015-0787) (NCT02782403)

Accelerated Phase

• BP1001 (2016-0644) (NCT02923986)
• K0706 (2016-0648) (NCT02629692)
• Axitinib + Bosutinib (2015-0787) (NCT02782403)

Blastic Phase

• Axitinib + Bosutinib (2015-0787) (NCT02782403)
• BP1001 (2016-0644) (NCT02923986)
• Bosutinib + Inotuzumab (2014-0435) (NCT02311998)
• K0706 (2016-0648) (NCT02629692)
• DS-3032B (2014-0565) (NCT02319369)

Imatinib failures with T315l mutations (any stage)

• K0706 (2016-0648) (NCT02629692)
• Ponatinib (2015-0212) (NCT02467270)
• Axitinib + Bosutinib (2015-0787) (NCT02782403)
• Oral ABL001 (2014-1019) (NCT02081378)

Minimal Residual Disease

• Ruxolitinib (2012-0697) (NCT01751425)

Myeloproliferative Diseases

• Ruxolitinib + Thalidomide (2017-0512) (NCT03069326)
• Pacritinib (2017-0320) (NCT03165734)
• Navitoclax (2017-0495) (NCT03222609)
• Ruxolitinib + PU-H71 (2017-0750) (NCT03373877)
• INCB050465 + Ruxolitinib (2016-0233) (NCT02718300)
• Sotatercept (ACE-011) (2012-0534) (NCT01712308)
• LCL-161 (2013-0612) (NCT02098161)
• SL-401 (2014-0976) (NCT02268253)
• Ruxolitinib + AZA (2012-0737) (NCT01787487)
• Luspatercept (ACE-536) (2017-0504) (NCT03194542)
• INCB054828 (2016-0635) (NCT03011372)
• BLU-285 (2015-0832) (NCT02561988)
• Rigosertib (2014-0546) (NCT02730884)
• Ruxolitinib vs Anagrelide (2017-0111) (NCT03123588)

Hemophagocytic Lymphohistiocytosis

• Alemtuzumab + Etoposide & Dexamethasone (2014-0989)